1. Home
  2. KXIN vs PSTV Comparison

KXIN vs PSTV Comparison

Compare KXIN & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

N/A

Current Price

$4.65

Market Cap

3.3M

ML Signal

N/A

Logo PLUS THERAPEUTICS Inc.

PSTV

PLUS THERAPEUTICS Inc.

N/A

Current Price

$0.57

Market Cap

61.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KXIN
PSTV
Founded
2015
1996
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
61.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KXIN
PSTV
Price
$4.65
$0.57
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.25
AVG Volume (30 Days)
1.1M
5.0M
Earning Date
11-26-2019
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,000.00
$5,258,000.00
Revenue This Year
N/A
$28.21
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$0.16
52 Week High
$75.00
$2.31

Technical Indicators

Market Signals
Indicator
KXIN
PSTV
Relative Strength Index (RSI) 63.75 47.30
Support Level $3.51 $0.54
Resistance Level $4.93 $0.60
Average True Range (ATR) 0.83 0.06
MACD -0.04 -0.01
Stochastic Oscillator 54.03 19.02

Price Performance

Historical Comparison
KXIN
PSTV

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: